5.00 score from hupso.pl for:
kaletra.com



HTML Content


Titlekaletra® (iopinavir/ritonavir)

Length: 30, Words: 3
Description learn about kaletra® (iopinavir/ritonavir). official site from abbvie inc. includes safety and prescribing information.

Length: 119, Words: 15
Keywords pusty
Robots
Charset UTF-8
Og Meta - Title pusty
Og Meta - Description pusty
Og Meta - Site name pusty
Tytuł powinien zawierać pomiędzy 10 a 70 znaków (ze spacjami), a mniej niż 12 słów w długości.
Meta opis powinien zawierać pomiędzy 50 a 160 znaków (łącznie ze spacjami), a mniej niż 24 słów w długości.
Kodowanie znaków powinny być określone , UTF-8 jest chyba najlepszy zestaw znaków, aby przejść z powodu UTF-8 jest bardziej międzynarodowy kodowaniem.
Otwarte obiekty wykresu powinny być obecne w stronie internetowej (więcej informacji na temat protokołu OpenGraph: http://ogp.me/)

SEO Content

Words/Characters 1886
Text/HTML 63.67 %
Headings H1 1
H2 0
H3 0
H4 1
H5 0
H6 7
H1
my journey with kaletra starts today
H2
H3
H4 you are leaving kaletra.com
H5
H6 important safety information
what is the most important information i should know about kaletra?
who should not take kaletra?
what should i tell my doctor before taking kaletra?
what are the possible side effects of kaletra?
important safety information
what is the most important information i should know about kaletra?
strong
b
i
em
Bolds strong 0
b 0
i 0
em 0
Zawartość strony internetowej powinno zawierać więcej niż 250 słów, z stopa tekst / kod jest wyższy niż 20%.
Pozycji używać znaczników (h1, h2, h3, ...), aby określić temat sekcji lub ustępów na stronie, ale zwykle, użyj mniej niż 6 dla każdego tagu pozycje zachować swoją stronę zwięzły.
Styl używać silnych i kursywy znaczniki podkreślić swoje słowa kluczowe swojej stronie, ale nie nadużywać (mniej niż 16 silnych tagi i 16 znaczników kursywy)

Statystyki strony

twitter:title pusty
twitter:description pusty
google+ itemprop=name pusty
Pliki zewnętrzne 4
Pliki CSS 2
Pliki javascript 2
Plik należy zmniejszyć całkowite odwołanie plików (CSS + JavaScript) do 7-8 maksymalnie.

Linki wewnętrzne i zewnętrzne

Linki 24
Linki wewnętrzne 12
Linki zewnętrzne 12
Linki bez atrybutu Title 24
Linki z atrybutem NOFOLLOW 0
Linki - Użyj atrybutu tytuł dla każdego łącza. Nofollow link jest link, który nie pozwala wyszukiwarkom boty zrealizują są odnośniki no follow. Należy zwracać uwagę na ich użytkowania

Linki wewnętrzne

close - javascript:void(0)
continue -
important safety information #isi
- /
1-866-kaletra
(1-866-525-3872)
tel:18665253872
1-877-343-1214 tel:18773431214
1-800-633-9110 tel:18006339110
1-800-222-6885 tel:18002226885
#kaletra
#isi
detailed important risk information #isi

Linki zewnętrzne

prescribing information http://www.rxabbvie.com/pdf/kaletratabpi.pdf
medication guide http://www.rxabbvie.com/pdf/kaletratab_medguide.pdf
www.abbviemedinfo.com http://www.abbviemedinfo.com
www.abbviepaf.org http://www.abbviepaf.org
full prescribing information http://www.rxabbvie.com/pdf/kaletratabpi.pdf
medication guide http://www.rxabbvie.com/pdf/kaletratab_medguide.pdf
www.fda.gov/medwatch http://www.fda.gov/medwatch
www.pparx.org http://www.pparx.org
terms of use http://www.abbvie.com/termsofuse.html
privacy policy http://www.abbvie.com/privacy.html
contact us https://www.abbvie.com/contactus.html
- http://www.abbvie.com/

Zdjęcia

Zdjęcia 5
Zdjęcia bez atrybutu ALT 4
Zdjęcia bez atrybutu TITLE 5
Korzystanie Obraz ALT i TITLE atrybutu dla każdego obrazu.

Zdjęcia bez atrybutu TITLE

/content/images/btn-modal-close.jpg
/content/images/hero-arrow-health-mobile.png
/content/images/hero-arrow-health-mobile.png
/content/images/img-logo-kaletra-desk.png
/content/images/img-logo-abbvie.jpg

Zdjęcia bez atrybutu ALT

/content/images/btn-modal-close.jpg
/content/images/hero-arrow-health-mobile.png
/content/images/hero-arrow-health-mobile.png
/content/images/img-logo-abbvie.jpg

Ranking:


Alexa Traffic
Daily Global Rank Trend
Daily Reach (Percent)









Majestic SEO











Text on page:

you are leaving kaletra.com the "continue" link below will take you out of the kaletra® (lopinavir/ritonavir) website operated by abbvie inc. you are now going to a third-party website. abbvie is providing this link. as a convenience to you, abbvie provides links from its websites to other third-party websites. information collected at third-party websites is not covered by our privacy policy, which applies solely to the information collected on this website. abbvie cannot guarantee the standards of every website link it provides or be responsible for the privacy practices or the content included on third-party websites. we encourage you to be aware when you leave this site and to read the privacy policy of any website that you may visit. close continue important safety information prescribing information medication guide my journey with kaletra starts today models throughout are for illustrative purposes only. what is kaletra? kaletra® (lopinavir/ritonavir) is a prescription hiv-1 medicine that is used with other hiv medicines to treat hiv-1 (human immunodeficiency virus) infection in adults and children 14 days of age and older. hiv is the virus that causes aids (acquired immune deficiency syndrome). kaletra is a type of hiv medicine called a protease inhibitor. kaletra contains two medicines: lopinavir and ritonavir. it is not known if kaletra is safe and effective in children under 14 days old. kaletra does not cure hiv infection or aids. people taking kaletra may develop infections or other conditions associated with hiv infection, including opportunistic infections (for example, pneumonia and herpes virus infections). copay card save up to $400 a month† for patients with questions, please call 1-866-kaletra (1-866-525-3872) for pharmacists with questions, please call trial card at 1-877-343-1214 †eligibility: available to patients with commercial prescription insurance coverage for kaletra. co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (for example, medicare, medicaid, tricare, department of defense or veteran’s affairs programs) or where prohibited by law. offer subject to change or discontinuance without notice. restrictions, including monthly maximums, may apply. this is not health insurance. abbvie medical information 1-800-633-9110 www.abbviemedinfo.com abbvie patient assistance foundation 1-800-222-6885 www.abbviepaf.org †eligibility: available to patients with commercial prescription insurance coverage for kaletra. co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state or government-funded insurance programs (for example, medicare, medicaid, tricare, department of defense or veteran’s affairs programs) or where prohibited by law. offer subject to change or discontinuance without notice. restrictions, including monthly maximums, may apply. this is not health insurance. important safety information what is the most important information i should know about kaletra? kaletra may cause serious side effects, including: interactions with other medicines. it is important to know the medicines that should not be taken with kaletra. for more information, see “who should not take kaletra?” changes in your heart rhythm and the electrical activity of your heart can occur when taking kaletra. these changes can lead to serious heart problems. your risk for these problems may be higher if you already have a history of abnormal heart rhythm or other types of heart disease, or if you take other medicines that can affect your heart rhythm while you take kaletra. tell your doctor right away if you experience dizziness, lightheadedness, fainting, and/or a sensation of abnormal heartbeats. who should not take kaletra? do not take kaletra if you are allergic to kaletra or any of its ingredients, including lopinavir or ritonavir. skin rashes, some of them severe, can occur in people who take kaletra. tell your doctor if you had a rash when you took another medicine for hiv or if you notice any skin rash when you take kaletra. do not take kaletra if you take any of the following medicines: alfuzosin (uroxatral®); cisapride (propulsid®, quicksolv®); ergot containing medicines, including ergotamine (cafergot® and others), dihydroergotamine (d.h.e. 45® or migranal®), and methylergonovine (methergine®); lovastatin (advicor®, altoprev®, or mevacor®); midazolam oral syrup; pimozide (orap®); rifampin (rifadin®, rifamate®, rifater®, or rimactane®); sildenafil (revatio®), when used for the treatment of pulmonary arterial hypertension; simvastatin (zocor®, vytorin®, or simcor®); products containing st. john’s wort (hypericum perforatum); or triazolam (halcion®). serious problems can happen if you or your child takes any of the medicines listed above with kaletra. what should i tell my doctor before taking kaletra? kaletra may not be right for you. tell your doctor about all of your medical conditions, including if you have any heart problems, including if you have a condition called congenital long qt syndrome; have or had pancreas problems, liver problems, including hepatitis b or hepatitis c, diabetes, hemophilia (people who take kaletra may have increased bleeding), or low potassium in your blood; or are pregnant or plan to become pregnant. if you take kaletra during pregnancy, you should talk with your doctor about how you can take part in an antiretroviral pregnancy registry. do not breastfeed, as it is not known if kaletra can be passed to the baby through your breast milk and whether it could harm your baby. also, mothers with hiv-1 should not breastfeed because hiv-1 can be passed to the baby in the breast milk. tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. many medicines interact with kaletra. do not start taking a new medicine without telling your doctor or pharmacist. your doctor can tell you if it is safe to take kaletra with other medicines. your doctor may need to change the dose of other medicines while you take kaletra. tell your doctor right away if you are taking: estrogen-based contraceptives (birth control pills and patches). you should use a different type or an extra form of birth control, since birth control pills or patches may not work as well while you take kaletra. talk to your doctor about how to prevent pregnancy while taking kaletra. medicines used for the treatment of erectile problems, such as avanafil (stendra®), sildenafil (viagra®), tadalafil (cialis®), or vardenafil (levitra®). there is an increased risk of certain problems when you take these medicines with kaletra, such as low blood pressure (dizziness or fainting), vision changes, and/or erections lasting more than 4 hours. tell your doctor right away if you experience any of these side effects. kaletra should not be taken once daily if you take carbamazepine (carbatrol®, epitol®, equetro®, tegretol®), phenobarbital (luminal®), phenytoin (dilantin®, phenytek®), efavirenz (atripla®, sustiva®), nevirapine (viramune®), or nelfinavir (viracept®). kaletra tablets should not be taken once daily if you are pregnant. you should not take kaletra oral solution if you are pregnant. kaletra oral solution contains propylene glycol and a large amount of alcohol. kaletra should not be given one time each day in children. when giving kaletra to your child, give kaletra exactly as prescribed. kaletra oral solution should not be given to babies younger than 14 days of age unless your doctor thinks it is right for your baby. babies taking kaletra oral solution may have side effects. call your doctor right away if your baby appears too sleepy or their breathing has changed. talk with your doctor if you take or plan to take metronidazole or disulfiram. you can have severe nausea and vomiting if you take these medicines with kaletra. this is not a complete list of medicines about which you should tell your doctor or pharmacist. for more information, refer to the kaletra medication guide. ask your doctor or pharmacist if you are not sure what medicines you are taking. know all the medicines that you take. keep a list of them to show doctors and pharmacists when you get a new medicine. do not start any new medicines while you are taking kaletra without first talking with your doctor. what are the possible side effects of kaletra? kaletra can cause serious side effects: kaletra may not be right for you. tell your doctor about all of your medical conditions. inflammation of the pancreas (pancreatitis), which may be serious and cause death, has occurred in some people who take kaletra. you have a higher chance of having pancreatitis if you have had it before. tell your doctor if you have nausea, vomiting, and/or abdominal pain, as these may be signs of pancreatitis. liver problems, including death, can happen in people who take kaletra. your doctor should do blood tests before and during your treatment with kaletra to check your liver function. some people with liver disease, such as hepatitis b or c, who take kaletra may have worsening liver disease. tell your doctor right away if you have any of the following signs and symptoms: loss of appetite, yellowing of skin or eyes (jaundice), dark-colored urine, pale-colored stools, itchy skin, and/or stomach area (abdominal) pain. new or more serious diabetes and high blood sugar (hyperglycemia) have occurred in some people who take protease inhibitors, including kaletra. tell your doctor if you notice an increase in thirst or urinate often while taking kaletra. changes in your immune system (immune reconstitution syndrome) can happen when you start taking hiv medicines. your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. call your doctor right away if you start having new symptoms after starting your hiv medicine. large increases in certain fat (triglycerides and cholesterol) levels in the blood have occurred in some people receiving kaletra. your doctor should do blood tests to check your cholesterol and triglyceride levels before you start taking kaletra and during your treatment. changes in body fat have been seen in some people who take anti-hiv therapy. the cause and long-term health effects of these conditions are not known at this time. increased bleeding has occurred in some people with hemophilia who take protease inhibitors, including kaletra. common side effects of kaletra include diarrhea, nausea, increased fats in blood (triglycerides or cholesterol), and vomiting. these are not all of the possible side effects of kaletra. this is the most important information to know about kaletra. for more information, talk with your doctor. kaletra tablets are a prescription medication. please see the full prescribing information, including the medication guide, for kaletra. you are encouraged to report negative side effects of prescription drugs to the fda. visit www.fda.gov/medwatch, or call 1-800-fda-1088. if you cannot afford your medication, contact www.pparx.org for assistance. you may also call 1-866-kaletra for more information, or abbvie customer service at 1-800-255-5162. reference: kaletra [package insert]. 1697387-1789661 terms of use | privacy policy | contact us copyright ©2015 abbvie inc. north chicago, il 60064 1980508-1830327 december 2015 please expand for detailed important risk information. important safety information what is the most important information i should know about kaletra? kaletra may cause serious side effects, including: interactions with other medicines. it is important to know the medicines that should not be taken with kaletra. for more information, see “who should not take kaletra?”


Here you find all texts from your page as Google (googlebot) and others search engines seen it.

Words density analysis:

Numbers of all words: 1814

One word

Two words phrases

Three words phrases

you - 5.79% (105)
kaletra - 3.97% (72)
the - 3.47% (63)
our - 2.87% (52)
for - 2.7% (49)
your - 2.59% (47)
not - 2.09% (38)
take - 1.98% (36)
and - 1.76% (32)
medicine - 1.6% (29)
with - 1.54% (28)
doctor - 1.49% (27)
kaletra. - 1.32% (24)
medicines - 1.27% (23)
are - 1.21% (22)
should - 1.05% (19)
may - 0.99% (18)
form - 0.99% (18)
information - 0.94% (17)
have - 0.88% (16)
including - 0.83% (15)
use - 0.83% (15)
out - 0.83% (15)
can - 0.83% (15)
all - 0.77% (14)
tell - 0.77% (14)
hiv - 0.72% (13)
taking - 0.66% (12)
other - 0.66% (12)
any - 0.66% (12)
who - 0.61% (11)
people - 0.55% (10)
now - 0.55% (10)
effects - 0.55% (10)
right - 0.55% (10)
abbvie - 0.55% (10)
site - 0.55% (10)
about - 0.5% (9)
important - 0.5% (9)
when - 0.5% (9)
problems - 0.5% (9)
website - 0.5% (9)
know - 0.5% (9)
change - 0.5% (9)
side - 0.5% (9)
heart - 0.44% (8)
these - 0.44% (8)
this - 0.44% (8)
prescription - 0.44% (8)
that - 0.44% (8)
call - 0.44% (8)
kaletra? - 0.44% (8)
cause - 0.39% (7)
more - 0.39% (7)
part - 0.39% (7)
some - 0.39% (7)
serious - 0.39% (7)
start - 0.39% (7)
age - 0.39% (7)
infection - 0.39% (7)
blood - 0.39% (7)
increase - 0.33% (6)
occur - 0.33% (6)
patient - 0.33% (6)
program - 0.33% (6)
while - 0.33% (6)
away - 0.33% (6)
what - 0.33% (6)
harm - 0.33% (6)
information, - 0.33% (6)
low - 0.33% (6)
insurance - 0.33% (6)
patients - 0.28% (5)
changes - 0.28% (5)
child - 0.28% (5)
pharmacist - 0.28% (5)
safe - 0.28% (5)
day - 0.28% (5)
baby - 0.28% (5)
oral - 0.28% (5)
treat - 0.28% (5)
problems, - 0.28% (5)
condition - 0.28% (5)
new - 0.28% (5)
liver - 0.28% (5)
medication - 0.28% (5)
talk - 0.28% (5)
medicines. - 0.22% (4)
fat - 0.22% (4)
breast - 0.22% (4)
skin - 0.22% (4)
taken - 0.22% (4)
occurred - 0.22% (4)
and/or - 0.22% (4)
notice - 0.22% (4)
ergot - 0.22% (4)
treatment - 0.22% (4)
before - 0.22% (4)
solution - 0.22% (4)
increased - 0.22% (4)
pregnant - 0.22% (4)
without - 0.22% (4)
see - 0.22% (4)
privacy - 0.22% (4)
link - 0.22% (4)
third-party - 0.22% (4)
infections - 0.22% (4)
please - 0.22% (4)
lopinavir - 0.22% (4)
available - 0.22% (4)
assistance - 0.22% (4)
immune - 0.22% (4)
programs - 0.22% (4)
hiv-1 - 0.22% (4)
conditions - 0.22% (4)
websites - 0.22% (4)
safety - 0.17% (3)
type - 0.17% (3)
interact - 0.17% (3)
which - 0.17% (3)
control - 0.17% (3)
known - 0.17% (3)
birth - 0.17% (3)
list - 0.17% (3)
vomiting - 0.17% (3)
such - 0.17% (3)
nausea - 0.17% (3)
protease - 0.17% (3)
has - 0.17% (3)
had - 0.17% (3)
rash - 0.17% (3)
pregnancy - 0.17% (3)
pregnant. - 0.17% (3)
days - 0.17% (3)
hepatitis - 0.17% (3)
guide - 0.17% (3)
long - 0.17% (3)
during - 0.17% (3)
used - 0.17% (3)
children - 0.17% (3)
virus - 0.17% (3)
too - 0.17% (3)
policy - 0.17% (3)
(for - 0.17% (3)
st. - 0.17% (3)
how - 0.17% (3)
time - 0.17% (3)
give - 0.17% (3)
happen - 0.17% (3)
under - 0.17% (3)
risk - 0.17% (3)
pancreatitis - 0.17% (3)
triglyceride - 0.17% (3)
cholesterol - 0.17% (3)
health - 0.17% (3)
example, - 0.17% (3)
most - 0.17% (3)
high - 0.17% (3)
receiving - 0.17% (3)
medical - 0.17% (3)
rhythm - 0.17% (3)
death, - 0.11% (2)
get - 0.11% (2)
symptoms - 0.11% (2)
daily - 0.11% (2)
once - 0.11% (2)
(triglycerides - 0.11% (2)
effects. - 0.11% (2)
than - 0.11% (2)
cholesterol) - 0.11% (2)
levels - 0.11% (2)
medicine. - 0.11% (2)
its - 0.11% (2)
tablets - 0.11% (2)
bleeding - 0.11% (2)
certain - 0.11% (2)
include - 0.11% (2)
patches - 0.11% (2)
fda. - 0.11% (2)
visit - 0.11% (2)
contact - 0.11% (2)
websites. - 0.11% (2)
pills - 0.11% (2)
also - 0.11% (2)
time. - 0.11% (2)
been - 0.11% (2)
body - 0.11% (2)
diabetes - 0.11% (2)
having - 0.11% (2)
refer - 0.11% (2)
nausea, - 0.11% (2)
severe - 0.11% (2)
abdominal - 0.11% (2)
signs - 0.11% (2)
tests - 0.11% (2)
check - 0.11% (2)
inc. - 0.11% (2)
babies - 0.11% (2)
website. - 0.11% (2)
(lopinavir/ritonavir) - 0.11% (2)
possible - 0.11% (2)
inhibitors, - 0.11% (2)
given - 0.11% (2)
large - 0.11% (2)
kaletra® - 0.11% (2)
doctor. - 0.11% (2)
system - 0.11% (2)
provides - 0.11% (2)
sure - 0.11% (2)
syndrome) - 0.11% (2)
tricare, - 0.11% (2)
prescribing - 0.11% (2)
pharmacist. - 0.11% (2)
maximums, - 0.11% (2)
“who - 0.11% (2)
†eligibility: - 0.11% (2)
commercial - 0.11% (2)
coverage - 0.11% (2)
co-pay - 0.11% (2)
interactions - 0.11% (2)
including: - 0.11% (2)
effects, - 0.11% (2)
reimbursement - 0.11% (2)
federal, - 0.11% (2)
state - 0.11% (2)
government-funded - 0.11% (2)
insurance. - 0.11% (2)
apply. - 0.11% (2)
monthly - 0.11% (2)
pharmacists - 0.11% (2)
restrictions, - 0.11% (2)
notice. - 0.11% (2)
medicare, - 0.11% (2)
discontinuance - 0.11% (2)
medicaid, - 0.11% (2)
subject - 0.11% (2)
offer - 0.11% (2)
law. - 0.11% (2)
prohibited - 0.11% (2)
where - 0.11% (2)
programs) - 0.11% (2)
affairs - 0.11% (2)
veteran’s - 0.11% (2)
defense - 0.11% (2)
kaletra?” - 0.11% (2)
1-866-kaletra - 0.11% (2)
collected - 0.11% (2)
aids - 0.11% (2)
breastfeed - 0.11% (2)
baby. - 0.11% (2)
milk - 0.11% (2)
cannot - 0.11% (2)
through - 0.11% (2)
encourage - 0.11% (2)
passed - 0.11% (2)
read - 0.11% (2)
plan - 0.11% (2)
continue - 0.11% (2)
department - 0.11% (2)
hemophilia - 0.11% (2)
pancreas - 0.11% (2)
you. - 0.11% (2)
sildenafil - 0.11% (2)
questions, - 0.11% (2)
medicines: - 0.11% (2)
card - 0.11% (2)
higher - 0.11% (2)
abnormal - 0.11% (2)
disease, - 0.11% (2)
ritonavir. - 0.11% (2)
experience - 0.11% (2)
contains - 0.11% (2)
ergotamine - 0.11% (2)
called - 0.11% (2)
them - 0.11% (2)
following - 0.11% (2)
deficiency - 0.11% (2)
containing - 0.11% (2)
medicines, - 0.11% (2)
2015 - 0.11% (2)
if you - 1.43% (26)
your doctor - 1.38% (25)
take kaletra - 0.94% (17)
you take - 0.72% (13)
tell you - 0.66% (12)
should not - 0.61% (11)
of the - 0.61% (11)
tell your - 0.61% (11)
you are - 0.55% (10)
side effects - 0.5% (9)
taking kaletra - 0.44% (8)
not be - 0.44% (8)
is not - 0.44% (8)
who take - 0.44% (8)
kaletra may - 0.39% (7)
take kaletra. - 0.39% (7)
people who - 0.33% (6)
right away - 0.33% (6)
away if - 0.33% (6)
you have - 0.33% (6)
doctor right - 0.33% (6)
not take - 0.33% (6)
some people - 0.33% (6)
when you - 0.33% (6)
to the - 0.28% (5)
other medicines - 0.28% (5)
for more - 0.28% (5)
in some - 0.28% (5)
more information, - 0.28% (5)
with kaletra. - 0.28% (5)
kaletra? kaletra - 0.28% (5)
any of - 0.28% (5)
effects of - 0.28% (5)
do not - 0.28% (5)
the medicines - 0.28% (5)
have a - 0.28% (5)
doctor about - 0.28% (5)
doctor if - 0.22% (4)
all of - 0.22% (4)
this is - 0.22% (4)
occurred in - 0.22% (4)
kaletra. you - 0.22% (4)
medicines that - 0.22% (4)
kaletra oral - 0.22% (4)
be taken - 0.22% (4)
oral solution - 0.22% (4)
hiv medicine - 0.22% (4)
in your - 0.22% (4)
with your - 0.22% (4)
you should - 0.22% (4)
is the - 0.22% (4)
while you - 0.22% (4)
with other - 0.22% (4)
to patients - 0.22% (4)
kaletra. tell - 0.22% (4)
available to - 0.22% (4)
take kaletra? - 0.17% (3)
third-party websites - 0.17% (3)
talk with - 0.17% (3)
safety information - 0.17% (3)
start taking - 0.17% (3)
the most - 0.17% (3)
important information - 0.17% (3)
your baby - 0.17% (3)
doctor or - 0.17% (3)
taking kaletra. - 0.17% (3)
know about - 0.17% (3)
not known - 0.17% (3)
of your - 0.17% (3)
may have - 0.17% (3)
other medicines. - 0.17% (3)
right for - 0.17% (3)
about all - 0.17% (3)
may not - 0.17% (3)
are pregnant - 0.17% (3)
problems, including - 0.17% (3)
heart rhythm - 0.17% (3)
serious side - 0.17% (3)
you can - 0.17% (3)
to change - 0.17% (3)
14 days - 0.17% (3)
(for example, - 0.17% (3)
to know - 0.17% (3)
changes in - 0.17% (3)
you start - 0.17% (3)
most important - 0.17% (3)
patients with - 0.17% (3)
for kaletra. - 0.17% (3)
are not - 0.17% (3)
cause serious - 0.17% (3)
may be - 0.17% (3)
important safety - 0.17% (3)
kaletra. for - 0.17% (3)
what is - 0.17% (3)
are taking - 0.17% (3)
is safe - 0.11% (2)
see “who - 0.11% (2)
kaletra® (lopinavir/ritonavir) - 0.11% (2)
medicines with - 0.11% (2)
you may - 0.11% (2)
abbvie inc. - 0.11% (2)
take these - 0.11% (2)
while taking - 0.11% (2)
to your - 0.11% (2)
information what - 0.11% (2)
should know - 0.11% (2)
information i - 0.11% (2)
kaletra with - 0.11% (2)
control pills - 0.11% (2)
to take - 0.11% (2)
about kaletra? - 0.11% (2)
side effects, - 0.11% (2)
including: interactions - 0.11% (2)
medicines. it - 0.11% (2)
is important - 0.11% (2)
medicines while - 0.11% (2)
that should - 0.11% (2)
taken with - 0.11% (2)
the possible - 0.11% (2)
have been - 0.11% (2)
including kaletra. - 0.11% (2)
kaletra should - 0.11% (2)
the kaletra - 0.11% (2)
plan to - 0.11% (2)
list of - 0.11% (2)
possible side - 0.11% (2)
be right - 0.11% (2)
for you. - 0.11% (2)
your medical - 0.11% (2)
should do - 0.11% (2)
call your - 0.11% (2)
blood tests - 0.11% (2)
side effects. - 0.11% (2)
during your - 0.11% (2)
kaletra to - 0.11% (2)
days of - 0.11% (2)
check your - 0.11% (2)
protease inhibitors, - 0.11% (2)
daily if - 0.11% (2)
of these - 0.11% (2)
these medicines - 0.11% (2)
and during - 0.11% (2)
to check - 0.11% (2)
once daily - 0.11% (2)
taken once - 0.11% (2)
medicines. your - 0.11% (2)
have any - 0.11% (2)
immune system - 0.11% (2)
notice an - 0.11% (2)
inhibitors, including - 0.11% (2)
take protease - 0.11% (2)
are pregnant. - 0.11% (2)
have occurred - 0.11% (2)
third-party websites. - 0.11% (2)
used for - 0.11% (2)
in the - 0.11% (2)
including monthly - 0.11% (2)
affairs programs) - 0.11% (2)
or where - 0.11% (2)
prohibited by - 0.11% (2)
law. offer - 0.11% (2)
subject to - 0.11% (2)
change or - 0.11% (2)
discontinuance without - 0.11% (2)
notice. restrictions, - 0.11% (2)
maximums, may - 0.11% (2)
of defense - 0.11% (2)
apply. this - 0.11% (2)
health insurance. - 0.11% (2)
commercial prescription - 0.11% (2)
insurance coverage - 0.11% (2)
co-pay assistance - 0.11% (2)
program is - 0.11% (2)
not available - 0.11% (2)
receiving prescription - 0.11% (2)
reimbursement under - 0.11% (2)
or veteran’s - 0.11% (2)
tricare, department - 0.11% (2)
state or - 0.11% (2)
with commercial - 0.11% (2)
that you - 0.11% (2)
a prescription - 0.11% (2)
of age - 0.11% (2)
known if - 0.11% (2)
kaletra is - 0.11% (2)
with questions, - 0.11% (2)
please call - 0.11% (2)
†eligibility: available - 0.11% (2)
prescription insurance - 0.11% (2)
medicare, medicaid, - 0.11% (2)
coverage for - 0.11% (2)
kaletra. co-pay - 0.11% (2)
assistance program - 0.11% (2)
patients receiving - 0.11% (2)
prescription reimbursement - 0.11% (2)
under any - 0.11% (2)
federal, state - 0.11% (2)
or government-funded - 0.11% (2)
insurance programs - 0.11% (2)
any federal, - 0.11% (2)
government-funded insurance - 0.11% (2)
not breastfeed - 0.11% (2)
your child - 0.11% (2)
information collected - 0.11% (2)
of abnormal - 0.11% (2)
or other - 0.11% (2)
you experience - 0.11% (2)
of them - 0.11% (2)
skin rash - 0.11% (2)
you to - 0.11% (2)
the treatment - 0.11% (2)
you. tell - 0.11% (2)
information, see - 0.11% (2)
website. abbvie - 0.11% (2)
including if - 0.11% (2)
hepatitis b - 0.11% (2)
or plan - 0.11% (2)
if kaletra - 0.11% (2)
can be - 0.11% (2)
passed to - 0.11% (2)
the baby - 0.11% (2)
breast milk - 0.11% (2)
“who should - 0.11% (2)
the privacy - 0.11% (2)
programs (for - 0.11% (2)
or discontinuance - 0.11% (2)
example, medicare, - 0.11% (2)
medicaid, tricare, - 0.11% (2)
department of - 0.11% (2)
defense or - 0.11% (2)
veteran’s affairs - 0.11% (2)
programs) or - 0.11% (2)
where prohibited - 0.11% (2)
by law. - 0.11% (2)
offer subject - 0.11% (2)
without notice. - 0.11% (2)
know the - 0.11% (2)
restrictions, including - 0.11% (2)
monthly maximums, - 0.11% (2)
may apply. - 0.11% (2)
not health - 0.11% (2)
i should - 0.11% (2)
may cause - 0.11% (2)
effects, including: - 0.11% (2)
interactions with - 0.11% (2)
important to - 0.11% (2)
take kaletra?” - 0.11% (2)
tell your doctor - 0.61% (11)
right away if - 0.33% (6)
if you take - 0.33% (6)
or if you - 0.33% (6)
people who take - 0.33% (6)
should not be - 0.33% (6)
doctor right away - 0.33% (6)
away if you - 0.33% (6)
not take kaletra - 0.33% (6)
your doctor right - 0.33% (6)
for more information, - 0.28% (5)
in some people - 0.28% (5)
if you have - 0.28% (5)
your doctor about - 0.28% (5)
side effects of - 0.22% (4)
kaletra oral solution - 0.22% (4)
any of the - 0.22% (4)
you take kaletra. - 0.22% (4)
doctor if you - 0.22% (4)
not be taken - 0.22% (4)
you have a - 0.22% (4)
available to patients - 0.22% (4)
with your doctor - 0.22% (4)
should not take - 0.22% (4)
kaletra. for more - 0.17% (3)
some people who - 0.17% (3)
your doctor or - 0.17% (3)
the most important - 0.17% (3)
doctor about all - 0.17% (3)
while you take - 0.17% (3)
kaletra? kaletra may - 0.17% (3)
talk with your - 0.17% (3)
about all of - 0.17% (3)
with other medicines. - 0.17% (3)
cause serious side - 0.17% (3)
is the most - 0.17% (3)
take kaletra. tell - 0.17% (3)
most important information - 0.17% (3)
this is not - 0.17% (3)
who take kaletra. - 0.17% (3)
for the treatment - 0.11% (2)
take these medicines - 0.11% (2)
once daily if - 0.11% (2)
medicines while you - 0.11% (2)
if you experience - 0.11% (2)
taken once daily - 0.11% (2)
kaletra. do not - 0.11% (2)
of the medicines - 0.11% (2)
days of age - 0.11% (2)
you are pregnant. - 0.11% (2)
call your doctor - 0.11% (2)
more information, see - 0.11% (2)
with kaletra. for - 0.11% (2)
medicines that should - 0.11% (2)
to know the - 0.11% (2)
it is important - 0.11% (2)
effects, including: interactions - 0.11% (2)
should know about - 0.11% (2)
important information i - 0.11% (2)
safety information what - 0.11% (2)
the possible side - 0.11% (2)
take protease inhibitors, - 0.11% (2)
doctor should do - 0.11% (2)
you start taking - 0.11% (2)
or plan to - 0.11% (2)
your immune system - 0.11% (2)
if you notice - 0.11% (2)
inhibitors, including kaletra. - 0.11% (2)
who take protease - 0.11% (2)
take kaletra may - 0.11% (2)
some people with - 0.11% (2)
do blood tests - 0.11% (2)
your doctor should - 0.11% (2)
take kaletra. you - 0.11% (2)
to the baby - 0.11% (2)
possible side effects - 0.11% (2)
with your doctor. - 0.11% (2)
you take these - 0.11% (2)
has occurred in - 0.11% (2)
right for you. - 0.11% (2)
can be passed - 0.11% (2)
law. offer subject - 0.11% (2)
or government-funded insurance - 0.11% (2)
any federal, state - 0.11% (2)
prescription reimbursement under - 0.11% (2)
to patients receiving - 0.11% (2)
is not available - 0.11% (2)
co-pay assistance program - 0.11% (2)
coverage for kaletra. - 0.11% (2)
commercial prescription insurance - 0.11% (2)
to patients with - 0.11% (2)
maximums, may apply. - 0.11% (2)
restrictions, including monthly - 0.11% (2)
discontinuance without notice. - 0.11% (2)
to change or - 0.11% (2)
where prohibited by - 0.11% (2)
medicare, medicaid, tricare, - 0.11% (2)
affairs programs) or - 0.11% (2)
defense or veteran’s - 0.11% (2)
tricare, department of - 0.11% (2)
example, medicare, medicaid, - 0.11% (2)
insurance programs (for - 0.11% (2)
state or government-funded - 0.11% (2)
under any federal, - 0.11% (2)
receiving prescription reimbursement - 0.11% (2)
program is not - 0.11% (2)
kaletra. co-pay assistance - 0.11% (2)
insurance coverage for - 0.11% (2)
with commercial prescription - 0.11% (2)
with questions, please - 0.11% (2)
programs (for example, - 0.11% (2)
department of defense - 0.11% (2)
passed to the - 0.11% (2)
is important to - 0.11% (2)
doctor about how - 0.11% (2)
kaletra may have - 0.11% (2)
including if you - 0.11% (2)
not known if - 0.11% (2)
may not be - 0.11% (2)
used for the - 0.11% (2)
rash when you - 0.11% (2)
take kaletra if - 0.11% (2)
your heart rhythm - 0.11% (2)
information, see “who - 0.11% (2)
be taken with - 0.11% (2)
that should not - 0.11% (2)
know the medicines - 0.11% (2)
other medicines. it - 0.11% (2)
or veteran’s affairs - 0.11% (2)
including: interactions with - 0.11% (2)
serious side effects, - 0.11% (2)
kaletra may cause - 0.11% (2)
know about kaletra? - 0.11% (2)
information i should - 0.11% (2)
information what is - 0.11% (2)
is not health - 0.11% (2)
may apply. this - 0.11% (2)
including monthly maximums, - 0.11% (2)
without notice. restrictions, - 0.11% (2)
change or discontinuance - 0.11% (2)
offer subject to - 0.11% (2)
prohibited by law. - 0.11% (2)
programs) or where - 0.11% (2)
“who should not - 0.11% (2)

Here you can find chart of all your popular one, two and three word phrases. Google and others search engines means your page is about words you use frequently.

Copyright © 2015-2016 hupso.pl. All rights reserved. FB | +G | Twitter

Hupso.pl jest serwisem internetowym, w którym jednym kliknieciem możesz szybko i łatwo sprawdź stronę www pod kątem SEO. Oferujemy darmowe pozycjonowanie stron internetowych oraz wycena domen i stron internetowych. Prowadzimy ranking polskich stron internetowych oraz ranking stron alexa.